Drug details

Inqovi (decitabine and cedazuridine tablets)

type of Antineoplastics DNA Methylation Inhibitor, Cytidine Deaminase Inhibitors

Inqovi (decitabine and cedazuridine) is a combination of a nucleoside metabolic inhibitor and a cytidine deaminase inhibitor used to treat adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French¬-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.

This drug may have the following side effects:

• nausea,
• rash,
• diarrhea,
• shortness of breath,
• dizziness,
• constipation,
• upper respiratory tract infection,
• joint pain,
• headache,
• fatigue,
• cough,
• bleeding,
• pneumonia,
• muscle pain,
• decreased appetite,
• fluid retention (edema),
• inflammation of mucus membranes,
• febrile neutropenia,
• increased transaminase,
• decreased leukocytes,
• decreased platelet count,
• decreased neutrophil count, and
• decreased hemoglobin

The following drugs are related to Inqovi, either as a replacement or used together:

• Clolar (clofarabine)
• Cytarabine (cytarabine)
• Sprycel (dasatinib)
• Gleevec (imatinib mesylate)
• Rydapt (midostaurin capsules)
• Oncaspar (pegaspargase)